$1.08
-0.04(-3.13%)
Mkt Cap $25M
$0.48
$1.75
52-Week Range
At a Glance
AI-generated8-K
Longeveron Inc. completed the initial closing of a private placement, issuing 6,013,384 shares of Class A common stock at $0.52 per share and 11,873.04 shares of Series A Non-Voting Convertible Preferred Stock convertible into 22,832,770 common shares for aggregate gross proceeds of approximately $15.9 million before fees. The financing extends cash runway into Q4 2026 past anticipated Phase 2b HLHS trial topline data, with potential $15 million second closing upon clinical and price milestones.$25M
Market Cap
$1M
Revenue
-$23M
Net Income
Employees25
Fundamentals
How The Business Makes Money
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001721484
ISINUS54303L2034
CUSIP54303L104
Phone305 909 0840
Address1951 NW 7th Avenue, Miami, FL, 33136, US
SEC EDGAR